Scientists reveal exact moment alcohol, smoking and lack of exercise starts to wreak havoc on your body
Many people employ the adage that you're only young once to justify making the most of your teens and twenties, yet new information from scientists gives a different meaning to the saying as the effects of smoking, drinking, and a lack of exercise are revealed.
It's not exactly rocket science to understand that unhealthy habits aren't the best for your body, yet it's often chalked off as something you can deal with and sort out down the line while current you doesn't have to face the problem.
Doctors have already warned that consuming too much unhealthy food can lead to a premature death, and even 'miracle' weight loss drugs like Ozempic can't make up for an unhealthy lifestyle.
However, one new scientific study has revealed the exact moment that your body begins to experience the long-term negative effects of harmful habits like smoking, excessive drinking, and a lack of exercise, and it's likely to shock you with how early it occurs.
As reported by the New York Post, the study published in Annals of Medicine by researchers from the Laurea University of Applied Sciences in Finland outlines that you begin to experience fast-tracked negative effects as early as your mid thirties.
Dr. Tiia Kekäläinen, lead author of the study, has argued that its findings highlight the importance of tackling these 'bad habits' as early as possible, as they can have an extremely detrimental effect on your body and health as you age.
Previous studies have linked high alcohol consumption with increased mortality rates, and worrying simulations showing the effect of binge drinking in the short term are certainly enough to give you pause for thought when it comes to your next pint or shot.
Alcohol, as illustrated by the study, is linked to outcomes including increased depressive symptoms, lower psychological well-being, lower self-rated health, and greater metabolic risk factors, proving to be a dangerous cocktail of health issues that'll hit you sooner than you might think.
If you're a keen smoker, you're also at risk of poorer mental well-being, whereas those who shy away from physical activity in their teens and twenties are often susceptible to health conditions as they grow older.
The research conducted within the paper concludes that these behaviors "were associated with poorer mental well-being and health," insisting that "preventing these behaviors early in adulthood and midlife is crucial to avoid their accumulation and subsequent health risks."
You certainly shouldn't see your life as a closed book though with no chance to amend your health, as Dr. Kekäläinen has urged that "it is never too late to change to healthier habits. Adopting healthier habits in midlife also has benefits for older age."
Therefore there's no reason you can't make a change in your life, as while the effects have been shown to begin relatively early on in life, they'll only continue to grow and get worse if a shift to a healthier lifestyle isn't made.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
22 minutes ago
- USA Today
Novo Nordisk halts Wegovy deal with Hims & Hers, triggering 31% stock drop
Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health HIMS.N, pushing Hims shares down 31% in morning trading. The two companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through a bundled offering on the telehealth company's platform. The end of the collaboration means Hims will no longer be able to sell branded Wegovy drugs. Novo said that Hims & Hers' decision to continue supplying doses of compounded semaglutide - the active ingredient in Wegovy - was not in accordance with the law because the drug was no longer in shortage. The U.S. Food and Drug Administration had allowed compounded versions made by pharmacies during the drug's shortage. In case you missed it: Wegovy weight-loss drug discounted to $199 until July, but there's a catch Earlier this month, Hims said that it would continue selling "personalized" doses of semaglutide, starting at around $165 a month. Hims has said personalized doses are allowed for patients who need different doses for clinical reasons such as limiting side effects. Hims & Hers shares were trading at $44.55 on Monday. Hims also sells liraglutide, a generic version of another older Novo diabetes drug that causes weight loss, as well as Eli Lilly's LLY.N rival Zepbound. Wall Street analysts have questioned whether Hims' offerings actually qualify as "personalized" and say it is unclear if Novo, which has said mass production of copies is breaking the law, will allow it. Hims & Hers was not immediately available for a comment. A U.S. federal judge on Friday rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and Drug Administration's decision to remove the drugs' active ingredient, semaglutide, from the shortage list. "Efforts will continue to make authentic, FDA-approved Wegovy directly available through NovoCare Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients," Novo said. Novo's share price fell following the announcement, extending an earlier decline to trade down 6.5% by 1315 GMT. Shares of Hims & Hers fell 22% to $50.02 in U.S. premarket hours. Reporting by Louise Breusch Rasmussen, Bhanvi Satija and Amina Niasse; Editing by Terje Solsvik, Catherine Evans and Aidan Lewis
Yahoo
36 minutes ago
- Yahoo
Mounjaro becomes available on the NHS: what to know and what to do if you're not eligible
Obesity remains one of the most pressing, and preventable, health challenges of our time. The UK is one of a number of countries undoubtedly struggling with it. It affects nearly every organ system in the body, contributing to cardiovascular conditions like coronary heart disease; musculoskeletal issues such as osteoarthritis and gout; and even the development of certain cancers, including of the breast, uterus and colon. Its impact on mental health is also significant. A few years ago, injectable weight-loss drugs entered clinical use and quickly captured public attention for their ability to promote rapid fat loss. Ozempic is available on the NHS, but only for managing type 2 diabetes. Wegovy is authorised for weight loss and cardiovascular risk reduction and is also available on the NHS, though access is currently limited to specialist weight management services. Now, a new option has emerged: Mounjaro, which is approved for both type 2 diabetes and weight loss. This dual-purpose drug is now available on the NHS, offering another potential tool in the fight against obesity. Demand is expected to be high. However, access will be limited at first, with strict eligibility criteria for NHS prescriptions. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Mounjaro (tirzepatide) is a once weekly injectable medication designed to help control blood-sugar levels. It works by boosting the secretion and effects of insulin, improving glycaemic control in people with Type 2 diabetes. It also slows gastric emptying — the process by which food leaves the stomach — and enhances feelings of fullness by acting on the brain. This combined effect reduces appetite and helps support weight loss. Compared to similar medications like Ozempic and Wegovy (both brand names for semaglutide), clinical trials found Mounjaro more effective, with some participants losing up to 20% of their body weight over a 72-week period. Read more: The NHS has introduced specific criteria to prioritise patients most in need. First, patients need a BMI of 40 or more (classified as morbid obesity). People from certain ethnic backgrounds, such as South Asian communities, may be eligible at a lower BMI due to higher clinical risk of health conditions. Second, at least four obesity-related health conditions must be diagnosed, including type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (abnormal cholesterol or triglyceride levels), cardiovascular disease and obstructive sleep apnoea. (Some of these conditions often occur together; for example, high blood pressure and cholesterol.) Patients are encouraged to check their BMI and confirm their diagnoses before contacting a GP. This helps ensure appointments are used effectively and discussions remain focused. While the current criteria are strict, there is optimism that eligibility will broaden in the coming years to include people with lower BMIs and fewer co-morbidities. The NHS continues to offer a comprehensive weight-loss programme, tiered according to BMI and previous attempts at weight loss. Don't underestimate the value of group-based programmes or community referrals – when a healthcare professional refers a patient to a community-based health service for further care or support – many of which can be accessed via your GP. These services, such as the NHS digital weight management programme, support both individuals and families and can be highly effective for sustainable fat loss. GPs may also refer patients to online courses and structured exercise programmes. Lifestyle interventions, including increased physical activity and healthier eating, remain cornerstones of obesity treatment and are critical for long-term success, even when medications are used. Read more: Higher tier interventions may be considered if lifestyle changes fail or if the patient has significant co-morbidities. This is where medications like Mounjaro, or private prescriptions, may become relevant – albeit that the cost of the latter may be a limiting factor for some. Other treatments include Orlistat, a medication that reduces fat absorption in the gut. This can be effective for some but often causes unpleasant side effects, such as oily stools and gastrointestinal upset Gastric banding or surgery may also result in significant, sustained weight loss, but they come with risks, can lead to surgical complications, and recovery can be demanding It's also important to recognise that drugs like Mounjaro aren't suitable for everyone. They can cause side effects significant enough for people to stop using them, and in some cases, they may not work at all. In this new era of faster, medication-assisted weight loss, we must remember that long-term change is about more than quick fixes. Sustainable success comes from consistent effort, willingness to change and methods that are both practical and lasting. Medications can help, sometimes dramatically, but they're not the only answer. A return to basics, with tailored support and realistic goals, remains as relevant as ever. So whether you qualify for Mounjaro, are trying lifestyle changes, or are exploring other options, remember this: the journey to better health is personal, gradual and worth it. This article is republished from The Conversation under a Creative Commons license. Read the original article. Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Yahoo
3 hours ago
- Yahoo
Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints
U.S.-listed shares of Novo Nordisk fell more than 5% Monday after the Ozempic and Wegovy maker released results for its newest weight-loss treatment. In a pair of trials, patients lost an average of 22.7% and 15.7% of their body weight over a 68-week period. Separately Monday, Novo Nordisk also said it was ending its partnership with Hims & Hers Health, accusing the digital pharmacy of "illegal mass compounding and deceptive marketing."Novo Nordisk's (NVO) U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the results of a Phase 3 trial for a new weight-loss treatment. The maker of Ozempic and Wegovy said that after a 68-week trial, obese and overweight patients who took CagriSema and followed a treatment plan lost an average of 22.7% of their body weight compared to 2.3% for those in the placebo group. About 40% of the group lost at least 25% of their body weight during the trial, and nearly a quarter lost 30% or more. Just 6% of the trial group stopped taking the drug, mainly due to gastrointestinal issues like nausea and constipation. Novo Nordisk also published results from a second trial Monday, evaluating the drug's effectiveness among overweight or obese patients with type 2 diabetes. At 68 weeks, the average weight loss was about 15.7% of a patient's body weight, and the company said the second trial had similar safety results as the first. Previous trial results for the drug weighed on Novo Nordisk's shares, as CagriSema has yet to achieve the average weight loss of 25% that the company has reportedly hoped for. Shares have also been pressured by trials showing that rival Eli Lilly's (LLY) Mounjaro and Zepbound, along with its drugs in development, are more effective at causing weight loss than Ozempic and Wegovy. U.S.-listed shares of Novo Nordisk are down 20% since the start of 2025 and have lost half their value over the past 12 months. Separately, Novo Nordisk said it has ended its partnership with digital pharmacy Hims & Hers Health (HIMS), and will no longer allow the company to prescribe Wegovy. The companies announced the collaboration in April, but on Monday Novo Nordisk accused Hims of "illegal mass compounding and deceptive marketing." Hims & Hers shares plummeted nearly 30% in recent trading. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
